PMCARDIO-PT1: Validation of PMcardio AI-assisted Clinical Assistant in Primary Care

Sponsor
Powerful Medical (Other)
Overall Status
Completed
CT.gov ID
NCT05329246
Collaborator
(none)
836
56
2
7.2
14.9
2.1

Study Details

Study Description

Brief Summary

This study aimed to analyze and investigate whether the use of the PMcardio clinical assistant leads to a more efficient patient management in primary care and more accessible specialised care compared to usual standards of care and to assess the reliability and safety of the PMcardio smartphone application in the primary care use environment. Additionally, to evaluate time savings and cost saving implications of increased availability of specialised care at the primary care level.

Condition or Disease Intervention/Treatment Phase
  • Device: AI-assisted Clinical Assistant PMcardio
N/A

Detailed Description

It is a multi-centric, physician-driven, patient-blinded randomized controlled trial of patients presenting to the general practitioner with typical cardiovascular symptoms (specifically, chest pain, syncope, palpitations, or shortness of breath) constituting an electrocardiogram examination. Eligible patients will be enrolled at the participating general practitioner clinics and managed either through the PMcardio platform with AI-assisted diagnostics, patient management recommendations or usual standard of care throughout their initial visit. Enrolled participants will be followed-up through health insurance billing codes and there will be no personal follow-up visits required. The aim of the study is to investigate whether the use of the PMcardio clinical assistant leads to a more efficient patient management in primary care and more accessible specialised care compared to usual standards of care and to assess the reliability and safety of the PMcardio smartphone application in the primary care use environment. Additionally, to assess time savings and cost saving implications of increased availability of specialised care at the primary care level.

Study Design

Study Type:
Interventional
Actual Enrollment :
836 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Validation of AI-assisted Clinical Assistant for Effective Management of Cardiovascular Diseases in Primary Health Care: PMcardio-1 Trial
Actual Study Start Date :
Nov 22, 2021
Actual Primary Completion Date :
Jun 30, 2022
Actual Study Completion Date :
Jun 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Experimental Intervention Group

AI-assisted interpretation of the ECG including the predicted ECG diagnoses, disease-specific anamnestic questions, and patient management recommendations for referral to secondary care, including suggestions for procedures and further diagnostic tests

Device: AI-assisted Clinical Assistant PMcardio
PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.

No Intervention: Control Group

The usual standard of care, with NO AI-based diagnosis or treatment recommendation available.

Outcome Measures

Primary Outcome Measures

  1. Time to first cardiovascular-related consultation [From randomization to enrollment period completion (up to 6 months)]

    Time from randomization to the first cardiovascular-related consultation or a follow-up visit at specialized physician in patients, where specialized consultation is indicated based on the general practitioner recommendation after using PMcardio application. The measurement will be assessed from the data received from the health insurance provider.

  2. Time to first cardiovascular-related diagnostic testing [From randomization to to enrollment period completion (up to 6 months)]

    Time from randomization to the first cardiovascular-related further diagnostic testing (laboratory parameters, ECG Holter, echocardiography).The measurement will be assessed from the data received from the health insurance provider

  3. Time to first cardiovascular-related hospitalization [From randomization to to enrollment period completion (up to 6 months)]

    Time from randomization to the first hospitalization in patients, where hospitalization is indicated, based on the general practitioner recommendation while using PMcardio application. The measurement will be assessed from the data received from the health insurance provider

  4. Time to first cardiovascular-related drug prescription [From randomization to to enrollment period completion (up to 6 months)]

    Time from randomization to the first cardiovascular-related drug prescription in patients, where drug prescription is indicated, based on the general practitioner recommendation while using PMcardio application. The measurement will be assessed from the data received from the health insurance provider

Secondary Outcome Measures

  1. Cost-effectiveness ratio and effect on cost savings [1 year]

    Cost-effectiveness ratio and projected effect on cost savings resulting from PMcardio remote specialist consultations measured based on Health Insurance data

  2. Reliability and safety of the PMcardio measured by system up-time [From the very first participants randomization to total follow-up time (up to 6 months)]

    The duration of time that the operating system of the application has been working and available in a reliable operating manner.

  3. Reliability and safety of the PMcardio measured by system failures [From the very first participants randomization to total follow-up time (up to 6 months)]

    The Number of failures by PMcardio application that caused the system to end abnormally.

  4. General practitioner satisfaction assessed by Client Satisfaction Questionnaire (CSQ-8 scale). [From randomization to study completion (up to 1 year)]

    The Client Satisfaction Questionnaire (CSQ-8 scale) measures general satisfaction of participating general practitioners with the functionality of the application at the end of the enrollment period. Possible scores range from 8 to 32, with higher scores indicating higher satisfaction with the application.

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male or Female aged 55 years or above.

  • Participant is willing and able to give informed consent for participation in the study.

  • Presenting to the GP with ANY of the following cardiovascular symptoms: palpitations, chest pain, syncope, shortness of breath.

  • Patients insured by Dôvera ZP or Union ZP health insurance providers.

Exclusion Criteria:
  • Reason for doing the ECG at the GP clinic is a routine examination or pre-operative assessment.

  • Participant does not present with cardiovascular symptoms: palpitations, chest pain, syncope, shortness of breath.

  • Participant is already included in the study due to a prior GP visit throughout the trial period (e.g., participant comes for a second visit to GP clinic due to cardiovascular symptoms).

  • Patients insured by VšZP health insurance provider

  • Female participants who are pregnant, lactating or planning pregnancy during the study.

  • Any other significant comorbidity, disease, or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 MUZMED s.r.o. Bardejov Slovakia
2 MAR-BID s.r.o. Bidovce Slovakia
3 SIMAMED, s.r.o. Borský Mikuláš Slovakia
4 SollarMED, s.r.o. Bratislava Slovakia
5 NÁGEL, s.r.o. Búč Slovakia
6 MEDIFARMA s.r.o. Dolný Kubín Slovakia
7 Promedicum, s.r.o. Hanušovce nad Topľou Slovakia
8 GP Humenné, s.r.o. Humenné Slovakia
9 LPSo spol. s r.o. Humenné Slovakia
10 MED - AID s.r.o. Humenné Slovakia
11 MUDr. Peter Križalkovič Hurbanovo Slovakia
12 MUDr. Ildikó Papáčková Kolárovo Slovakia
13 BELLIS-med s.r.o. Komárno Slovakia
14 MEDIKONTAKT, s.r.o. Komárno Slovakia
15 IRS - Medicínska činnosť s.r.o. Košice Slovakia
16 MUCOMED s.r.o. Košice Slovakia
17 MUDr. Ján Telepovský Košice Slovakia
18 SANABITUR, s.r.o. Križovany nad Dudváhom Slovakia
19 Anahata s.r.o. Lenartovce Slovakia
20 FONTHIS, s.r.o. Levice Slovakia
21 MUDr. Mária Schmidtová, s.r.o. Martin Slovakia
22 Vaša ambulancia, s. r. o. Martin Slovakia
23 MUDr. Ondrej Gajdoš Medzev Slovakia
24 Medic I+H s.r.o. Medzilaborce Slovakia
25 JANMED, s.r.o. Michalovce Slovakia
26 Cardio Clinic s.r.o. Moldava nad Bodvou Slovakia
27 G.Praktik s.r.o. Moldava nad Bodvou Slovakia
28 HODOSI-MED s.r.o Moldava nad Bodvou Slovakia
29 Tamice,s.r.o. Moldava nad Bodvou Slovakia
30 TOMICI s.r.o. Nesvady Slovakia
31 Timimed s. r. o. Nitra Slovakia
32 VERKIAD s.r.o. Nitra Slovakia
33 VALETUDO s.r.o. Nitrianske Hrnčiarovce Slovakia
34 RODMED s.r.o. Nové Zámky Slovakia
35 LEK - NO, s.r.o. Námestovo Slovakia
36 Duo medical s.r.o. Pezinok Slovakia
37 PALMED, s.r.o. Podolínec Slovakia
38 MEDIPRAX s.r.o Poprad Slovakia
39 PULSE medicine, s.r.o Poprad Slovakia
40 GP - PRAKTIK, s.r.o. Prešov Slovakia
41 KNG s.r.o. Prešov Slovakia
42 MDPRAK, s.r.o. Prešov Slovakia
43 RM - MEDICAL s.r.o. Prievidza Slovakia
44 CorMedicus s.r.o. Ruskov Slovakia
45 Jklinik s.r.o Ružomberok Slovakia
46 PT Care s.r.o. Spišský Hrušov Slovakia
47 MUDr. Boris Piteľ Stakčín Slovakia
48 MEDICATEK s.r.o. Starý Tekov Slovakia
49 VINOVA Group s.r.o. Strekov Slovakia
50 GPII Medical s.r.o. Tekovské Lužany Slovakia
51 MUDr. Peter MARKO, s.r.o. Veľká Lomnica Slovakia
52 Resutík s.r.o. Veľký Krtíš Slovakia
53 MUDr. Viera Čuchranová Vinné Slovakia
54 JOMED, spol. s r.o. Vranov nad Topľou Slovakia
55 AVK MEDIC, s.r.o. Štúrovo Slovakia
56 MUDr. Orság Juraj, s.r.o. Želiezovce Slovakia

Sponsors and Collaborators

  • Powerful Medical

Investigators

  • Principal Investigator: Robert Hatala, PhD, Chief Scientist and Founder

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

None provided.
Responsible Party:
Powerful Medical
ClinicalTrials.gov Identifier:
NCT05329246
Other Study ID Numbers:
  • 202106001
  • CIV-21-09-037810
First Posted:
Apr 14, 2022
Last Update Posted:
Aug 2, 2022
Last Verified:
Jul 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Powerful Medical
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 2, 2022